RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer

In metastatic colorectal cancer, RAS and BRAF mutations cause resistance to anti‐EGFR therapies, such as cetuximab. Heterogeneity in RAS and BRAF mutations might explain nonresponse in a subset of patients receiving cetuximab. Analyzing mutations in plasma‐derived circulating tumor DNA (ctDNA) could...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Erik J. vanHelden, Lindsay Angus, C. Willemien Menke‐van der Houven van Oordt, Daniëlle A. M. Heideman, Eline Boon, Suzanne C. vanEs, Sandra A. Radema, Carla M. L. vanHerpen, Derk Jan A. deGroot, Elisabeth G. E. deVries, Maurice P. H. M. Jansen, Stefan Sleijfer, Henk M. W. Verheul
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2019-11-01
Edice:	Molecular Oncology
Témata:	biomarkers BRAF cell‐free DNA cetuximab colorectal cancer RAS mutations
On-line přístup:	https://doi.org/10.1002/1878-0261.12550
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!